Table 1.
Population’s characteristics.
| Mean ± SE | (%) | |
|---|---|---|
| Age (years) | 66 ± 9 | |
| Male (%) | 88% | |
| Heart rate (bpm) | 70 ± 14 | |
| Systolic blood pressure (mmHg) | 123 ± 20 | |
| Ischemic etiology (%) | 43% | |
| Hypertension (%) | 57% | |
| COPD (%) | 31% | |
| Diabetes (%.) | 31% | |
| ICD/CRT-D (%) | 50% | |
| LVEF (%) | 34 ± 9 | |
| LVESV | 120 ± 56 | |
| LVEDV | 176 ± 70 | |
| E/E’ ratio | 15.5 ± 5.7 | |
| PAsP | 34 ± 12 | |
| TAPSE | 16.5 ± 4.05 | |
| Creatinine (mg/dl) | 1.16 ± 4.04 | |
| ACE inhibitor (%) | 68% | |
| ARB (%) | 32% | |
| Furosemide (%) | 85% | |
| MRA (%) | 57% | |
| Betablocker (%) | 96% | |
| Ivabradine (%.) | 29% | |
| Digoxin (%) | 13% |
Legend: COPD: Chronic Obstructive Pulmonary Disease; ICD/CRT-D: Implantable Cardioverter-Defibrillator/Cardiac Resynchronization Therapy-Defibrillator; LVEF: Left Ventricular Ejection Fraction; LVEDV: Left Ventricle End-Diastolic Volume; LVESV: Left Ventricular End-Systolic Volume; E/E’ ratio: trans-mitral to mitral annular early diastolic velocity ratio; PAsP: Pulmonary Artery systolic Pressure; TAPSE: Tricuspid Annular Plane Systolic Excursion; ACE: Angiotensin Converting Enzyme; ARB: Angiotensin II Receptor Blocker; MRA: Mineralocorticoid Receptor Antagonist.